Oakmont Investment Advisors Inc. Invests $2.11 Million in Stryker Corporation $SYK

Oakmont Investment Advisors Inc. purchased a new stake in Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 6,709 shares of the medical technology company’s stock, valued at approximately $2,112,000. Stryker accounts for about 1.5% of Oakmont Investment Advisors Inc.’s holdings, making the stock its 17th biggest holding.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. VanderPol Investments L.L.C. lifted its holdings in shares of Stryker by 1.4% in the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after purchasing an additional 28 shares in the last quarter. KCM Investment Advisors LLC increased its stake in Stryker by 1.5% in the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after buying an additional 28 shares during the last quarter. Rossby Financial LCC boosted its position in Stryker by 6.6% in the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after purchasing an additional 28 shares during the last quarter. Tcfg Wealth Management LLC grew its position in Stryker by 2.7% during the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after buying an additional 29 shares during the period. Finally, ICW Investment Advisors LLC increased its stake in shares of Stryker by 0.6% during the 4th quarter. ICW Investment Advisors LLC now owns 5,096 shares of the medical technology company’s stock worth $1,791,000 after purchasing an additional 30 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of SYK stock opened at $302.92 on Friday. The firm has a market cap of $116.19 billion, a P/E ratio of 31.39, a P/E/G ratio of 1.93 and a beta of 0.76. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.37. The business’s 50 day moving average price is $328.84 and its 200-day moving average price is $329.73. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter in the prior year, the company earned $3.13 earnings per share. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts anticipate that Stryker Corporation will post 15.03 earnings per share for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Stryker in a research note on Friday, July 31st. BTIG Research lowered their price target on Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. BMO Capital Markets initiated coverage on shares of Stryker in a research report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price target for the company. Wolfe Research cut shares of Stryker from an “outperform” rating to a “peer perform” rating in a report on Thursday, August 13th. Finally, Truist Financial upped their price target on shares of Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $386.28.

Insider Activity

In related news, insider Debra King sold 826 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Ronda Stryker sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the sale, the director owned 2,251,375 shares of the company’s stock, valued at $765,692,637.50. This trade represents a 2.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 351,267 shares of company stock valued at $118,197,701. Corporate insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.